or search for allinseo plug in" Body Health Advisor » Blog Archive » Advice on Health and Body Matters

7 Guidelines for Treating Low Back Pain - Does Your Doctor Know Them?

The American College of Physicians recently released its guidelines for diagnosing and treating lower back pain. These guidelines are the result of a long and intensive review of research on lower back pain. I have translated them from “doctorese” for you benefit.

1. Treating professionals should take a good history and do a thorough physical exam. The purpose of that exam is to identify which of three categories of back pain you have. The three groups are back pain with no specific cause, back pain with radiculopathy or spinal stenosis, or back pain with some other specific cause.

2. If you are in the first (non-specific) group, your doctor should not order routine imaging tests like x- rays or MRI’s.

3. If your back pain is accompanied by worsening neurological deficits or evidence of some serious underlying medical condition, then the doctor should order diagnostic and imaging tests.

4. If you have lower back pain and radiculopathy, then MRI’s or CT scans should be ordered only if you are a candidate for and epidural injection or surgery.

5. Your doctor should give you evidence-based information on low back pain. This information should include the expected course of their pain, advice to remain active, and a review of possible self-care alternatives.

6. Your doctor should consider medications that have been shown to be effective, and should use them along with self-care options. Medication should be accompanied by an assessment of your pain levels, and you should be advised of all the pros and cons of the medications. Recommended started medications for most people are an NSAID or acetaminophen.

7. If improvement is not seen with this program, your doctor should consider recommending other pain management alternatives. For chronic back pain, this include relaxation, acupuncture, yoga, massage therapy, exercise, and spinal manipulation.

It’s to your advantage to be an informed patient and know these guidelines. They tell you what information your doctor should be getting from you, and what issues should be addressed directly with you as you and your doctor develop your treatment plan.

These guidelines are a summary of those approved by the American Pain Society. They were released in October 2007, and have been published a number of places, including the Annals of Internal Medicine. Consider printing a copy of this article and keeping it for reference, and to discuss with your doctor if you have any questions.

Barry Hughes, Ph.D. is a psychologist and publisher of Chronic Pain Alternatives, which provides “Resources and Information for People with Chronic Pain.” He has built this site using Site Build It!, the easiest way to translate your passion onto the Web.
 

Technorati Tags:

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Leave a Reply

  • Kombiglyze XR as a treatment for type 2 diabetes in adults approved
    Bristol-Myers, AstraZeneca Receive FDA Approval For Diabetes Drug. The AP (11/5) reported, “Drug makers Bristol-Myers Squibb Co. and AstraZeneca PLC said Friday that they received US marketing approval for a once-a-day diabetes drug that combines the starter diabetes drug metformin with the companies’ newer drug Onglyza.” The Food and Drug […]
  • Type 2 Diabetes is increasing in China
    Global research and advisory firm Decision Resources has predicted that the Chinese type 2 diabetes market will grow from $1.4 billion in 2009 to $2.5 billion in 2014. According to the Emerging Markets report entitled Type 2 Diabetes in China, this growth is attributed to an increasing drug-treated population, expanding medical insurance coverage and the [.. […]
  • Avastatin for Breast cancer
    Roche Stands To Lose Substantial Sales Should Regulatory Bodies Revoke License For Avastin. Dow Jones Newswire(12/8, Mijuk) reported that should FDA and European regulators revoke the license for Avastin (bevacizumab) as a treatment for breast cancer, then the drug’s maker, Roche Holding AG, may stand to lose more than one billion Swiss francs in sales […]
  • FDA: Tainted products marketed as dietary supplements potentially dangerous
    Agency working with trade associations to increase company vigilance and protect public In a letter sent today to dietary supplement manufacturers, the U.S. Food and Drug Administration expressed concern about undeclared or deceptively labeled ingredients in products marketed as dietary supplements. These substances include the active ingredients in FDA-a […]
H1N1 Fraudulent Products update







Tai Chi WeightLoss